GlassScriptPhysician profile
Troy Evans Boovy
NPI 1215055637
$4,766.08
in general payments reported to CMS, 2019-2025
15 companies · $1,658 in 2025
The $1,658 reported for 2025 was more than what 89% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $619 · 2022: $730 · 2023: $953 · 2024: $808 · 2025: $1,658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,188 · Education: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,187.59 |
| Education | $230.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $826.19 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $748.47 | 2021-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Neurocrine Biosciences, INC. | $655.01 | 2022-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $628.11 | 2021-2025 | Uzedy, Austedo Xr, Austedo |
| E.R. Squibb & Sons, L.L.C. | $462.21 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $387.50 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $338.16 | 2021-2025 | Invega Sustenna |
| Vanda Pharmaceuticals INC. | $211.80 | 2021-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $181.16 | 2021-2025 | |
| Indivior INC. | $157.02 | 2022-2024 | Perseris |
| Sunovion Pharmaceuticals INC. | $62.73 | 2021-2022 | |
| Lundbeck LLC | $38.55 | 2021-2022 | |
| Noven Therapeutics, LLC | $32.35 | 2022 | |
| Axsome Therapeutics, INC. | $21.82 | 2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $15.00 | 2023 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Troy Boovy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.